Newron Pharmaceuticals further expands its intellectual property portfolio for Evenamide with a new EU composition of matter ...
Compliance teams, however, cannot police AI usage across the economy. They cannot audit every client model or validate every ...
Ad hoc announcement pursuant to Art. 53 LR EP4615820 "Crystalline Forms of Evenamide" is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being investigated in Newron's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback